Aberrant Immunoglobulin G Glycosylation in Multiple Sclerosis.

Abstract

A hallmark of the inflammatory response in multiple sclerosis (MS) is the presence of intrathecal Immunoglobulin G (IgG) antibodies and oligoclonal bands (OCBs). The biological activity of IgGs is modulated by changes in glycosylation. Using multiple immunoassays with common lectins for sialylation and galactosylation, we investigated levels of IgG glycosylation in 28 MS and 37 control sera as well as paired CSF and serum. We demonstrated the presence of significantly lower levels of IgG sialylation in MS CSF compared to paired serum. Further, we showed that in MS there was no correlation between sialylated IgG and total IgG antibodies, or between sialylated IgG in CSF and serum. ELISA with native IgG antibodies showed significantly higher levels of sialylated and galactosylated IgG in MS compared to other neurological disorders and normal healthy controls. We conclude that lower levels of sialylated intrathecal IgG and higher levels of serum IgG galactosylation in MS may play significant role in disease pathogenesis. The unique IgG glycosylation profiles suggest a complexed nature of the IgG antibodies which may influence its effector functions in MS.

• Authors: Peter G E Kennedy, Michael Graner, Tiffany Pointon, Xiaomeng Li, Kayo Tanimoto, Kathryn Dennison, Gina Im, Anthony Fringuello, Wenbo Zhou, Arin Graner, Stefan Sillau, Timothy Vollmer, Xiaoli Yu
• Journal: Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology (J Neuroimmune Pharmacol) Vol. 17 Issue 1-2 Pg. 218-227 (06 2022) ISSN: 1557-1904 [Electronic] United States
• PMID: 33942224 (Publication Type: Journal Article)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Chemical References

• Immunoglobulin G

Topics

• Humans
• Immunoglobulin G
• Multiple Sclerosis